Strata Skin Sciences (SSKN) to Release Earnings on Wednesday

Strata Skin Sciences (NASDAQ:SSKN) is anticipated to issue its Q1 2026 results after the market closes on Wednesday, May 13th. Analysts expect the company to announce earnings of ($0.36) per share and revenue of $5.26 million for the quarter. Parties may review the information on the company’s upcoming Q1 2026 earning report for the latest details on the call scheduled for Wednesday, May 13, 2026 at 5:00 PM ET.

Strata Skin Sciences Price Performance

Shares of NASDAQ:SSKN opened at $0.15 on Wednesday. The business’s 50 day simple moving average is $0.21 and its 200-day simple moving average is $0.93. The firm has a market capitalization of $887,910.40, a price-to-earnings ratio of -0.06 and a beta of -0.05. The company has a debt-to-equity ratio of 10.22, a current ratio of 0.95 and a quick ratio of 0.75. Strata Skin Sciences has a 12 month low of $0.11 and a 12 month high of $3.86.

Institutional Investors Weigh In On Strata Skin Sciences

An institutional investor recently bought a new position in Strata Skin Sciences stock. Susquehanna International Group LLP bought a new stake in Strata Skin Sciences, Inc. (NASDAQ:SSKN) during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 12,426 shares of the medical device company’s stock, valued at approximately $26,000. Susquehanna International Group LLP owned approximately 0.24% of Strata Skin Sciences as of its most recent filing with the Securities and Exchange Commission. 32.43% of the stock is owned by institutional investors.

Analyst Ratings Changes

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Strata Skin Sciences in a research note on Thursday, January 22nd. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock currently has a consensus rating of “Sell”.

Strata Skin Sciences Company Profile

Strata Skin Sciences, Inc is a medical technology company headquartered in Edison, New Jersey, that specializes in developing and commercializing dermatological devices and therapies. The company’s flagship offering is the XTRAC® excimer laser system, an FDA‐cleared, 308-nanometer ultraviolet light device used to treat skin conditions such as vitiligo and psoriasis. Strata’s product suite also includes associated accessories and disposables, as well as clinical services and training programs designed to support dermatology practices and improve patient outcomes.

Strata Skin Sciences expanded its portfolio and market presence through the strategic acquisition of PhotoMedex in 2019, bringing together complementary phototherapy and energy-based technologies under one roof.